|Manufacturer:||Eli Lilly and Company|
Reconstitution — Glucagon for Injection (rDNA origin) should be
Discard any unused portion.
Glucagon is indicated as a treatment for severe
hypoglycemia.Because patients with type 1
diabetes may have less of an increase in blood glucose levels compared with
a stable type 2 patient, supplementary carbohydrate should be given as soon
as possible, especially to a pediatric patient.
-- A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
Diabetes Mellitus, Insulin-Dependent
-- subtype of diabetes mellitus that is characterized by insulin deficiency; it is manifested by the sudden onset of severe hyperglycemia, rapid progression to diabetic ketoacidosis, and death unless treated with insulin; the disease may occur at any age, but is most common in childhood or adolescence.
Glucagon is contraindicated in patients with known
hypersensitivity to it or in patients with known pheochromocytoma.
-- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
-- A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Glucagon should be administered cautiously to patients
with a history suggestive of insulinoma, pheochromocytoma, or both.
with insulinoma, intravenous administration of glucagon may produce an initial
increase in blood glucose; however, because of glucagon's hyperglycemic
effect the insulinoma may release insulin and cause subsequent hypoglycemia.
A patient developing symptoms of hypoglycemia after a dose of glucagon should
be given glucose orally, intravenously, or by gavage, whichever is most appropriate.
This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor.
It should not to be used for self-diagnosis or treatment.